Q-omics provides the consensus-scored MIR4731 profile across patient tissues and cancer cell-line models. MIR4731 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, MIR4731 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, MIR4731 RNA expression shows 11,958 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUSC, BRCA, and LSCC as cancer lineages where MIR4731 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4731 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4731 survival associations across molecular data types. MIR4731 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4731 RNA expression–survival associations across cancer types. High MIR4731 expression shows unfavorable associations in LUSC, CESC, READ, LIHC and ACC, but favorable associations in ESCA. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for MIR4731 RNA expression.
This table summarizes MIR4731 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4731. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4731 shows lower tumor expression in BRCA and LUSC. The BRCA box plot shows higher MIR4731 RNA expression in normal versus tumor tissue (log2 FC = −1.714, t-test p < 0.001).
This table shows molecular features associated with MIR4731 in patient tissues and cancer cell lines. In patient samples, MIR4731 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
